Your browser doesn't support javascript.
loading
Oxomollugin, an oxidized substance in mollugin, inhibited LPS-induced NF-κB activation via the suppressive effects on essential activation factors of TLR4 signaling.
Nakajima, Yuki; Tsuboi, Naohide; Katori, Kumiko; Waili, Maigunuer; Nugroho, Alfarius Eko; Takahashi, Kazunori; Nishino, Hitomi; Hirasawa, Yusuke; Kawasaki, Yoko; Goda, Yukihiro; Kaneda, Toshio; Morita, Hiroshi.
Affiliation
  • Nakajima Y; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
  • Tsuboi N; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
  • Katori K; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
  • Waili M; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
  • Nugroho AE; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
  • Takahashi K; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
  • Nishino H; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
  • Hirasawa Y; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan.
  • Kawasaki Y; National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
  • Goda Y; National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
  • Kaneda T; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan. kaneda@hoshi.ac.jp.
  • Morita H; School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo, 142-8501, Japan. moritah@hoshi.ac.jp.
J Nat Med ; 78(3): 568-575, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38564154
ABSTRACT
Oxomollugin is a degraded product of mollugin and was found to be an active compound that inhibits LPS-induced NF-κB activation. In this study, we investigated the inhibitory activity of oxomollugin, focusing on TLR4 signaling pathway, resulting in NF-κB activation. Oxomollugin inhibited the LPS-induced association of essential factors for initial activation of TLR4 signaling, MyD88, IRAK4 and TRAF6. Furthermore, oxomollugin showed suppressive effects on LPS-induced modification of IRAK1, IRAK2 and TRAF6, LPS-induced association of TRAF6-TAK1/TAB2, and followed by IKKα/ß phosphorylation, which critical in signal transduction leading to LPS-induced NF-κB activation. The consistent results suggested that oxomollugin inhibits LPS-induced NF-κB activation via the suppression against signal transduction in TLR4 signaling pathway.The activities of oxomollugin reported in this study provides a deeper understanding on biological activity of mollugin derivatives as anti-inflammatory compounds.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Signal Transduction / Lipopolysaccharides / NF-kappa B / Toll-Like Receptor 4 Language: En Journal: J Nat Med Year: 2024 Type: Article Affiliation country: Japan

Full text: 1 Database: MEDLINE Main subject: Signal Transduction / Lipopolysaccharides / NF-kappa B / Toll-Like Receptor 4 Language: En Journal: J Nat Med Year: 2024 Type: Article Affiliation country: Japan